{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:33:50Z","timestamp":1760549630189},"reference-count":11,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T00:00:00Z","timestamp":1413936000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:sec id=\"S0924270814000283_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>A case of agomelatine-induced hepatotoxicity is described in a 47-year female patient who has received the drug, 25 mg\/day, for 4 months, for the treatment of depression.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270814000283_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>The patient was admitted to the Department of Gastroenterology because of fatigue and nausea, with concomitant elevation of alanine aminotransferase (ALT), 550 U\/L, and asparagine aminotransferase (AST), 300 U\/L.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270814000283_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Liver biopsy showed diffuse lymphocyte infiltration in the dilated portal spaces without lesion of hepatic lobules. Several weeks after stopping agomelatine, the liver enzymes returned to normal. Subsequently, small gallstones in common bile duct were detected and removed by the endoscopic sphincterotomy.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270814000283_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>It is hypothesized that choledocholithiasis could theoretically increase a risk of developing agomelatine-induced hepatotoxicity in this patient. Any pre-existing liver disease should be a contraindication for treatment with agomelatine.<\/jats:p><\/jats:sec>","DOI":"10.1017\/neu.2014.28","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T10:20:11Z","timestamp":1413973211000},"page":"56-59","update-policy":"http:\/\/dx.doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":5,"title":["Agomelatine-induced liver injury in a patient with choledocholithiasis"],"prefix":"10.1017","volume":"27","author":[{"given":"Piotr","family":"Eder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Permoda-Osip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemyslaw","family":"Majewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Linke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz K.","family":"Rybakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,10,22]]},"reference":[{"key":"S0924270814000283_ref4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-0033-1353156","article-title":"Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions","volume":"46","author":"Gahr","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"S0924270814000283_ref9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4103\/0971-3026.36868","article-title":"The role of combining MR cholangiopancreatography and T1W imaging in detecting common bile duct micro-stones","volume":"17","author":"Xindao","year":"2007","journal-title":"Indian J Radiol Imaging"},{"key":"S0924270814000283_ref6","unstructured":"Valoxan\/Thymanax . European Medicines Agency (EMA) 2013;702809:3\/73."},{"key":"S0924270814000283_ref3","unstructured":"Agomelatine (Valdoxan\/Thymanax): risk of dose-related hepatotoxicity and liver failure \u2013 updated warnings and monitoring guidance. Drug Safety Update 2013;6:A1."},{"key":"S0924270814000283_ref7","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34944"},{"key":"S0924270814000283_ref1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2012.18.3.249"},{"key":"S0924270814000283_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.02.010"},{"key":"S0924270814000283_ref8","doi-asserted-by":"publisher","DOI":"10.1186\/ar3282"},{"key":"S0924270814000283_ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-013-0344-0"},{"key":"S0924270814000283_ref2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13050709"},{"key":"S0924270814000283_ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0960327112472994"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270814000283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T18:54:21Z","timestamp":1555872861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270814000283\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,22]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0924270814000283"],"URL":"https:\/\/doi.org\/10.1017\/neu.2014.28","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,22]]},"assertion":[{"value":"\u00a9 Scandinavian College of Neuropsychopharmacology 2014\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}